Cargando…

Efficacy of Spironolactone as an Adjunctive Therapy to Risperidone to Improve Symptoms of Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled, Clinical Trial

Objective: Spironolactone (C24H32O4S), a potent mineralocorticoid receptor (MR) inhibitor, is a potassium-sparing diuretic that is traditionally used to treat fluid build-up in the body or for its anti-androgenic properties. This study is a double-blind, placebo-controlled, randomized clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zandifar, Atefeh, Badrfam, Rahim, Sanjari Moghaddam, Hossein, Akhondzadeh, Shahin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994842/ https://www.ncbi.nlm.nih.gov/pubmed/35480128 http://dx.doi.org/10.18502/ijps.v17i1.8045

Ejemplares similares

Efficacy of Gemfibrozil as an Adjunct to Sertraline in Major Depressive Disorder, A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial
por: Zandifar, Atefeh, et al.
Publicado: (2021)

The efficacy of vitamin B6 as an adjunctive therapy to lithium in improving the symptoms of acute mania in patients with bipolar disorder, type 1; a double‐blind, randomized, placebo‐controlled, clinical trial
por: Badrfam, Rahim, et al.
Publicado: (2021)

Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Arabzadeh, Somaye, et al.
Publicado: (2018)

COVID-19: Considering the prevalence of schizophrenia in the coming decades
por: Zandifar, Atefeh, et al.
Publicado: (2020)

Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial
por: Samaei, Areoo, et al.
Publicado: (2020)

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial
por: Raghuthaman, G., et al.
Publicado: (2015)

Asia and COVID-19; The need to continue mental health care to prevent the spread of suicide in the elderly
por: Badrfam, Rahim, et al.
Publicado: (2020)

From encephalitis lethargica to COVID-19: Is there another epidemic ahead?
por: Badrfam, Rahim, et al.
Publicado: (2020)

COVID-19 and Melancholia: Different Perception of the Concept of Stigma and Loss
por: Badrfam, Rahim, et al.
Publicado: (2020)

Stigma Over COVID-19; New Conception Beyond Individual Sense
por: Badrfam, Rahim, et al.
Publicado: (2020)

COVID-19 and mental health: An Iranian perspective
por: Badrfam, Rahim, et al.
Publicado: (2020)

Iranian mental health during the COVID-19 epidemic
por: Zandifar, Atefeh, et al.
Publicado: (2020)

Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial
por: Kianimehr, Gilda, et al.
Publicado: (2014)

Mental Health Care for Medical Staff in Iran during the COVID-19 Pandemic; Different Performance in Alborz Province
por: Zandifar, Atefeh, et al.
Publicado: (2020)

Mental Health of Medical Workers in COVID-19 Pandemic: Restrictions and Barriers
por: Badrfam, Rahim, et al.
Publicado: (2020)

Status of stigma on the health care workers related to COVID-19 at the first wave of the pandemic in Iran: A qualitative study
por: Badrfam, Rahim, et al.
Publicado: (2022)

Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute mania: a double blind and placebo controlled trial
por: Akhondzadeh, Shahin, et al.
Publicado: (2003)

Low-Dose Quetiapine in the Treatment of SSRI-Induced Bruxism and Mandibular Dystonia: Case Series
por: Zandifar, Atefeh, et al.
Publicado: (2018)

Interdisciplinary Collaboration between Bench and Bedside in the COVID-19 Pandemic
por: Sanjari Moghaddam, Hossein, et al.
Publicado: (2023)

Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial
por: Mortazavi, Mehran, et al.
Publicado: (2015)

Creutzfeldt-Jakob Disease after Dental Procedure along with the Initial Manifestations of Psychiatric Disorder: A Case Report
por: Badrfam, Rahim, et al.
Publicado: (2021)

Suicidal ideation, burnout, and their correlation among health care workers at the end of the fourth wave of the COVID-19 pandemic in Alborz Province, Iran
por: Badrfam, Rahim, et al.
Publicado: (2023)

Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double‐blind, randomized, placebo‐controlled trial
por: Abdallah, Mahmoud S., et al.
Publicado: (2022)

Prevalence and Associated Factors of Posttraumatic Stress Symptoms and Stigma among Health Care Workers in Contact with COVID-19 Patients
por: Zandifar, Atefeh, et al.
Publicado: (2020)

Femicomfort in the Treatment of Premenstrual Syndromes: A Double-Blind, Randomized and Placebo Controlled Trial
por: Kashani, Ladan, et al.
Publicado: (2010)

Anti N‐Methyl‐D‐Aspartate (NMDA) receptor encephalitis: from psychosis to cognitive impairment
por: Vahabi, Zahra, et al.
Publicado: (2021)

Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2017)

Comorbidity of adult ADHD and substance use disorder in a sample of inpatients bipolar disorder in Iran
por: Badrfam, Rahim, et al.
Publicado: (2022)

Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial [ISRCTN64132371]
por: Akhondzadeh, Shahin, et al.
Publicado: (2004)

Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study
por: Zhu, Weiwei, et al.
Publicado: (2014)

Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia
por: Zhang, Hongyan, et al.
Publicado: (2011)

Spironolactone for adult female acne (SAFA): protocol for a double-blind, placebo-controlled, phase III randomised study of spironolactone as systemic therapy for acne in adult women
por: Renz, Susanne, et al.
Publicado: (2021)

Effect of Spironolactone in Resistant Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial (ASPIRANT-EXT)
por: Václavík, Jan, et al.
Publicado: (2014)

Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial
por: Rezaei, Farzin, et al.
Publicado: (2015)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

RISPERIDONE IN SCHIZOPHRENIA
por: Kumar, P.N. Suresh
Publicado: (1999)

Randomized, double‐blind, 6‐week non‐inferiority study of lurasidone and risperidone for the treatment of schizophrenia
por: Feng, Yuan, et al.
Publicado: (2020)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
por: Gabriel, Adel
Publicado: (2010)

Effect of Cuscuta epithymum Acquainted with Risperidone on the Improvement of Clinical Symptoms and Cognitive Impairment in Patients with Schizophrenia: A Triple-Blind Randomized Placebo-Controlled Trial
por: Parvizi, Maedeh, et al.
Publicado: (2019)

Efficacy and Safety of Oral Combination of Yohimbine and L-arginine (SX) for the Treatment of Erectile Dysfunction: a multicenter, randomized, double blind, placebo-controlled clinical trial
por: Akhondzadeh, Shahin, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_jsosh6ihvb6vql0l5fkj14etrn